5-Acetylamino-7-(2,4,6-triisopropyl-benzenesulfonyloxy)-3-(2,3, 5-tri-O-acetyl-β-D-ribofuranosyl)thiazolo[4,5-d]pyrimidin-2-one | 533897-44-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-Acetylamino-7-(2,4,6-triisopropyl-benzenesulfonyloxy)-3-(2,3, 5-tri-O-acetyl-β-D-ribofuranosyl)thiazolo[4,5-d]pyrimidin-2-one
• 英文别名: 5-acetylamino-7-(2,4,6-triisopropyl-benzenesulfonyloxy)-3-(2,3,5-tri-O-acetyl-3-βD-ribofuranosyl)thiazolo[4,5-d]pyrimidin-2-one；5-Acetylamino-7-(2,4,6-triisopropyl-benzenesulfonyloxy)-3-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)thiazolo[4,5-d]pyrimidin-2-one；5-Acetylamino-7-(2,4,6-triisopropyl-benzenesulfonyloxy)-3-(2,3,5-tri-o-acetyl-beta-d-ribofuranosyl)thiazolo[4,5-d]pyrimidin-2-one；[(2R,3R,4R,5R)-5-[5-acetamido-2-oxo-7-[2,4,6-tri(propan-2-yl)phenyl]sulfonyloxy-[1,3]thiazolo[4,5-d]pyrimidin-3-yl]-3,4-diacetyloxyoxolan-2-yl]methyl acetate
• CAS: 533897-44-8
• 化学式: C₃₃H₄₂N₄O₁₂S₂
• 分子量: 750.848
• InChiKey: JIFUGURTZMPKGZ-YSRRZRNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  51
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  240
• 氢给体数：
  1
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  5-Acetylamino-7-(2,4,6-triisopropyl-benzenesulfonyloxy)-3-(2,3, 5-tri-O-acetyl-β-D-ribofuranosyl)thiazolo[4,5-d]pyrimidin-2-one 以79%的产率得到5-Acetylamino-7-pyrrolidino-3-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2-one
  参考文献：
  名称：

  3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof

  摘要：

  这项发明涉及3-β-D-核糖呋喃基噻唑并[4,5-d]吡啶嘧啶核苷及含有这种化合物的具有免疫调节活性的药物组合物。该发明还涉及这种化合物和组合物的治疗或预防用途，以及通过给予这种化合物的有效量来治疗本文描述的疾病和紊乱的方法。

  公开号：

  US20050070556A1
• 作为产物：
  描述：

  7-thia-8-oxoguanosine 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 5.5h， 生成 5-Acetylamino-7-(2,4,6-triisopropyl-benzenesulfonyloxy)-3-(2,3, 5-tri-O-acetyl-β-D-ribofuranosyl)thiazolo[4,5-d]pyrimidin-2-one
  参考文献：
  名称：

  [EN] 3-beta-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
  [FR] NUCLEOSIDES 3-20051222WO03045968A1ANADYS PHARMACEUTICALS INC [US]20030605WX1-20XUS5041426AROBINS ROLAND K [US], et al19910820compounds 6,7,41,42X1,2,12XWO03045968A1ANADYS PHARMACEUTICALS INC [US]20030605"Remington's Pharmaceutical Sciences"Remington's Pharmaceutical SciencesBARANOV ET AL., CHEM. HET. COMPOUNDS, vol. 11, 1975, pages 73BARANOV ET AL.CHEM. HET. COMPOUNDS19751173

  摘要：

  本发明涉及3-ß-D-核糖呋喃噻唑[4,5-d]吡啶嘧啶核苷和含有此类化合物的药物组合物，具有免疫调节活性。本发明还涉及这类化合物和组合物的治疗或预防用途，以及通过给予这类化合物的有效剂量来治疗本文所述的疾病和疾病的方法。

  公开号：

  WO2005121162A1

文献信息

• 3-beta-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof
  申请人：——

  公开号：US20030199461A1

  公开（公告）日：2003-10-23

  The invention is directed to 3-&bgr;-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  该发明涉及3-β-D-核糖呋喃基噻唑[4,5-d]吡啶核苷及含有这种化合物的药物组合物，这些化合物具有免疫调节活性。该发明还涉及使用这些化合物和组合物的治疗或预防用途，并通过给予这些化合物的有效剂量来治疗所述疾病和紊乱的方法。
• 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof
  申请人：Averett R. Devron

  公开号：US20050182001A1

  公开（公告）日：2005-08-18

  The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  这项发明涉及3-β-D-核糖呋喃噻唑[4,5-d]吡啶嘧啶核苷及含有这种化合物的药物组合物，其具有免疫调节活性。该发明还涉及使用这些化合物和组合物进行治疗或预防，以及通过给予有效剂量的这些化合物来治疗所述的疾病和疾病描述的方法。
• 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof
  申请人：Averett Devron R.

  公开号：US20080070852A1

  公开（公告）日：2008-03-20

  The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  本发明涉及3-β-D-核糖呋喃基噻唑[4,5-d]嘧啶核苷及含有这种化合物的药物组合物，其具有免疫调节活性。本发明还涉及使用这种化合物和组合物进行治疗或预防，以及通过给予有效剂量的这种化合物来治疗本文所述的疾病和障碍的方法。
• 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF
  申请人：Averet Devron R.

  公开号：US20080255063A1

  公开（公告）日：2008-10-16

  The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  本发明涉及3-β-D-核糖呋喃噻唑并[4,5-d]嘧啶核苷及含有这种化合物的制药组合物，该化合物具有免疫调节活性。本发明还涉及使用这种化合物和组合物的治疗或预防用途，以及通过给予有效剂量的这种化合物来治疗本文所述的疾病和障碍的方法。
• 3-beta-D-Ribofuranosylthiazalo [4-5-d] pyrimidine nucleosides and uses thereof
  申请人：Averett R. Devron

  公开号：US20080090844A1

  公开（公告）日：2008-04-17

  The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

  本发明涉及3-β-D-核糖呋喃噻唑[4,5-d]吡啶核苷及含有此类化合物的药物组合物，其具有免疫调节活性。本发明还涉及使用此类化合物和组合物进行治疗或预防所述疾病和障碍的方法，并通过给予有效剂量的此类化合物来进行治疗。